REG - Wellnex Life Limited - Trading Update

Wellnex LifeAnnouncement

12/05/2025 14:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250512:nRSL3086Ia&default-theme=true

RNS Number : 3086I  Wellnex Life Limited  12 May 2025

 

 

 

ASX/AIM Announcement
 
   12 May 2025

 

 

Wellnex Life Limited (ASX/AIM:WNX)

 

Trading Update

 

Wellnex Life Limited ("Wellnex" or the "Company") (ASX:WNX  AIM:WNX),  an
innovative consumer healthcare business with a track record for developing,
licensing, and marketing products and brands to customers in the growing
healthcare market segment, is pleased to provide a trading update for the
period January to April 2025 (the "Period").

 

Highlights

●    Revenue for the Period of $8.0 million represents an increase of 46%
compared to the same period 12 months earlier ("PCP") of $5.4 million

●    Gross margins for the Period of $2.99 million, an increase of 55% on
PCP of $1.93 million

●    Revenue for April 2025 was up 75% to $2.57 million compared to April
2024, with an equivalent growth in gross margins of 74% from $0.48 million to
$1.13 million

●    Revenue for FY25 to April was $19.9 million with gross margins of
$5.7 million, despite a previously disclosed slower than anticipated start to
2025 and a strategic increase in trade investment in 1H FY25 reducing gross
margins

●    Successful admission on 21 March 2025 to the AIM Market of the London
Stock Exchange ("AIM"), with funds used to extinguish circa $13 million in
debt with direct savings of circ $1.4 million in annual costs

FY25 Update
 
 

 

Wellnex continues to see growth across its whole business with increasing
demand for its innovative products and brands, both domestically and during
the early stages of its international expansion plans.

 

Revenue for the Period was $8.0 million, an increase of 46% compared to the
PCP of $5.4 million, with gross margins for the Period increasing 55% to $2.99
million compared to $1.93 million for the PCP.

 

Wellnex, in April 2025, saw a 75% increase in revenue compared to April 2024,
with revenue of $2.57 million and gross margins of $1.13 million compared to
revenue of $1.47 million and gross margins of $0.65 million in April 2024.

 

 

FY25 revenue to April 2025 of $19.9 million was impacted by a previously
disclosed slower than anticipated start to 2025  due to stock outages, delays
in delivering new products and exacerbated by the IPO process. Wellnex is
pleased to announce that these headwinds have now subsided. The gross margins
for FY25 to April were $5.7 million; while this was a significant improvement
for the same period 12 months ago, it was impacted by a strategic decision by
the Company to increase trade investment in 1H FY25, resulting in gross margin
of 22% for 1H FY25. Trade investment in the second half of FY25 has returned
to normalised levels, resulting in gross margins for the Period increasing to
c.37%.

 

Outlook

 

Wellnex continues to see growth across the whole business which the Board
expects to continue for the remainder of FY25 and into FY26, with increasing
demand for the Company's brands and products.

Wellnex's brands continue to expand their distribution in the Australian
market and the Company is in the process of preparing to enter the UK and
European markets in FY26.

IP licensing continues to see growing demands and opportunities from customers
for the Company's innovative products in conjunction with the recent
international expansion of these arrangements in H1FY25.

Wellnex, with its growing revenue, will continue to refine and optimize its
approach to trade investment to maximise gross margins, in conjunction with a
reduction of OPEX (from normal operations) to enhance the Company's future
perfomance.

Commenting on the progress, Joint CEO Director Zack Bozinovski said: "We
continue to see growth across the whole business in both brands and IP
licensing opportunities and we are confident that this will continue, which we
expect to enhance the future performance of the business. With the recent
completion of the dual listing on the AIM Market and the removal of c. $13
million in liabilities, the Company is well positioned to take advantage of
the opportunities in the growing consumer healthcare market."

This ASX/AIM announcement has been authorised by the Board of Wellnex Life
Limited (ASX/AIM:WNX).

 

For further information, please contact:

 

Wellnex Life Limited (ASX:WNX)
 Reach Markets

George Karafotias or Zack Bozinovski                         T:
1300 805 9419

Joint Chief Executive Officers
    E: IR@reachmarkets.com.au

P: +61 3 8399 9419

E: george.k@Wellnexlife.com.au (mailto:george.k@Wellnexlife.com.au)

 

UK Investors

 

Strand Hanson (Financial & Nominated Advisor)

James Harris / Richard Johnson / Robert Collins Tel: +44 (0) 20 7409 3494

 

Orana Corporate LLP (Joint Broker)
   swykeham@oranacorp.com (mailto:swykeham@oranacorp.com)

Sebastian Wykeham

 

S.P. Angel Corporate Finance LLP (Joint Broker)            Tel: +44
(0)20 3470 0470

David Hignell / Vadim Alexandre

 

The information contained within this announcement is deemed by the Company to
constitute inside information pursuant to article 7 of EU Regulation 596/2014
as it forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 as amended.

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFLFSFEAIFLIE